ArticleMicroorganisms2018
Sequential Combined Effect of Phages and Antibiotics on the Inactivation of
Article in Microorganisms, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 76 citations in OpenAlex.
- Phenotypic and Genotypic Characterization of Novel Polyvalent Bacteriophages With PotentFrontiers in cellular and infection microbiology · 2021Trial
- Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage-Driven Resistance.Microbial biotechnology · 2026Article
- Ecological partitioning enables phage-antibiotic cooperation in a human Pseudomonas infection.Nature communications · 2026Article
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Phage Therapy as a Novel Alternative to Antibiotics Through Adaptive Evolution and Fitness Trade-Offs.Antibiotics (Basel, Switzerland) · 2025Review
- Marine Bacteriophages as Next-Generation Therapeutics: Insights into Antimicrobial Potential and Application.Viruses · 2025Review
- Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.International journal of molecular sciences · 2025Review
- The Potential of Phage Treatment to Inactivate Planktonic and Biofilm-FormingMicroorganisms · 2024Article
- Mitomycin C as an Anti-Persister Strategy againstAntibiotics (Basel, Switzerland) · 2024Article
- Bacteriophages and Their Host Range in Multidrug-Resistant Bacterial Disease Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.Journal of clinical laboratory analysis · 2023Review
- Molecular studies of phages-Frontiers in microbiology · 2023Article
- Modelling the synergistic effect of bacteriophage and antibiotics on bacteria: Killers and drivers of resistance evolution.PLoS computational biology · 2022Article
- NovelPharmaceutics · 2022Article
- Phage-Antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency.Antibiotics (Basel, Switzerland) · 2022Review
- Combined Effect of Phage phT4A and Pressure-Based Strategies in the Inhibition ofAntibiotics (Basel, Switzerland) · 2022Article
- Phenotypic and Genomic Comparison ofViruses · 2021Article
- Friends or Foes? Rapid Determination of Dissimilar Colistin and Ciprofloxacin Antagonism ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Double-Layer Agar (DLA) Modifications for the First Step of the Phage-Antibiotic Synergy (PAS) Identification.Antibiotics (Basel, Switzerland) · 2021Article
- Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae.Antimicrobial agents and chemotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of antibiotic resistance in bacteria is a global concern. The use of bacteriophages (or phages) alone or combined with antibiotics is consolidating itself as an alternative approach to inactivate antibiotic-resistant bacteria. However, phage-resistant mutants have been considered as a major threat when phage treatment is employed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.